Intervacc AB (SE:IVACC)
:IVACC
Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr0.92
-kr0.06(-5.24%)
At close: 4:00 PM EST
kr0.92
-kr0.06(-5.24%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume791.15K
Average Volume (3M)373.34K
Market Cap
kr456.69M
Enterprise Valuekr277.34M
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr44.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityA very low debt load and EUR/SEK 253.2M of equity provide financial flexibility and a multi-quarter runway for clinical and commercial activities. This durable strength lowers refinancing risk, supports R&D and partner commercialization, and cushions short-term losses.
Improving Free Cash Flow TrendA marked improvement in free cash flow (≈+48%) signals management progress in expense control or operational efficiency. Because FCF tracks reported losses, the improvement reflects real cash dynamics, reducing the scale of future financing needs if the trend continues.
Commercialized Flagship Vaccine With Partner ModelHaving a marketed product (Strangvac) and partner distribution creates an existing revenue stream and demonstrates regulatory/commercial validation. The partner model enables scalable market access with lower fixed selling costs and potential milestone or royalty income over time.
Bears Say
Significant And Sustained Cash BurnVery large negative operating and free cash flows create an ongoing need for external funding. Persistent cash burn erodes liquidity and forces dilution or debt raises, which can constrain strategic options and pressure investment in commercialization or pipeline advancement.
Deep Structural Losses And Negative Gross ProfitNegative gross profit and extreme operating losses suggest underlying unit economics are unfavourable. Without margin recovery, continued losses will steadily deplete equity despite a strong balance sheet, undermining long-term viability unless product economics improve.
Modest And Declining Revenue BaseA small, shrinking revenue base limits scale benefits and makes fixed-cost absorption harder. Reliance on a single primary product and partner commercialization increases revenue concentration risk, constraining the company's path to sustainable profitability absent meaningful market expansion.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr456.69M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―